Next Steps for Immunotherapy in Glioblastoma

Toni Q. Cao; Derek A. Wainwright; Catalina Lee-Chang; Jason Miska; Adam M. Sonabend; Amy B. Heimberger; Rimas V. Lukas

doi:10.3390/cancers14164023

Next Steps for Immunotherapy in Glioblastoma

Toni Q. Cao^*, Derek A. Wainwright, Catalina Lee-Chang, Jason Miska, Adam M. Sonabend, Amy B. Heimberger, Rimas V. Lukas

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

Original language	English (US)
Article number	4023
Journal	Cancers
Volume	14
Issue number	16
DOIs	https://doi.org/10.3390/cancers14164023
State	Published - Aug 2022

Funding

A.M.S. reports authorship of patents filed by Northwestern University regarding immunotherapy for gliomas. Research support has kindly been provided by BMS, Agenus, and Carthera. Additionally, he has received philanthropic support from Agenus. A.B.H. serves on the advisory board of Caris Life Sciences, and WCG Oncology Advisory Board receives royalty and milestone payments from DNAtrix for the licensing of “Biomarkers and combination therapies using oncolytic virus and immunomodulation” (11,065,285) and is supported by research grants from Celularity, Codiak Biosciences, and AbbVie. Other support has been provided by Moleculin and Carthera, and she has received consulting fees in the last year from Novocure and Istari Oncology. She additionally has active patents for “miRNA for treating cancer and for use with adoptive immunotherapies” (9,675,633) and “Concurrent chemotherapy and immunotherapy (9,399,662) with a patent pending for “Low intensity ultrasound combination cancer therapies” (International application #PCT/US2022/019435 and US 63/158,642). RVL serves on the scientific advisory board for Merck. Additionally, he is on the speakers’ bureau for Novocure and Merck. He receives research support from BMS. T.Q.C., D.A.W., C.L.C., and J.M. have no conflicts of interest to disclose. This work was supported by the following NIH grants: P30CA060553, NS110703, CA120813, NS120547, and P50CA221747.

Keywords

glioblastoma
immune system
immunotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers14164023

Cite this

@article{528ecef49da646538461baff5dc40823,

title = "Next Steps for Immunotherapy in Glioblastoma",

abstract = "Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.",

keywords = "glioblastoma, immune system, immunotherapy",

author = "Cao, {Toni Q.} and Wainwright, {Derek A.} and Catalina Lee-Chang and Jason Miska and Sonabend, {Adam M.} and Heimberger, {Amy B.} and Lukas, {Rimas V.}",

note = "Funding Information: A.M.S. reports authorship of patents filed by Northwestern University regarding immunotherapy for gliomas. Research support has kindly been provided by BMS, Agenus, and Carthera. Additionally, he has received philanthropic support from Agenus. A.B.H. serves on the advisory board of Caris Life Sciences, and WCG Oncology Advisory Board receives royalty and milestone payments from DNAtrix for the licensing of “Biomarkers and combination therapies using oncolytic virus and immunomodulation” (11,065,285) and is supported by research grants from Celularity, Codiak Biosciences, and AbbVie. Other support has been provided by Moleculin and Carthera, and she has received consulting fees in the last year from Novocure and Istari Oncology. She additionally has active patents for “miRNA for treating cancer and for use with adoptive immunotherapies” (9,675,633) and “Concurrent chemotherapy and immunotherapy (9,399,662) with a patent pending for “Low intensity ultrasound combination cancer therapies” (International application #PCT/US2022/019435 and US 63/158,642). RVL serves on the scientific advisory board for Merck. Additionally, he is on the speakers{\textquoteright} bureau for Novocure and Merck. He receives research support from BMS. T.Q.C., D.A.W., C.L.C., and J.M. have no conflicts of interest to disclose. Funding Information: This work was supported by the following NIH grants: P30CA060553, NS110703, CA120813, NS120547, and P50CA221747. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = aug,

doi = "10.3390/cancers14164023",

language = "English (US)",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "16",

}

TY - JOUR

T1 - Next Steps for Immunotherapy in Glioblastoma

AU - Cao, Toni Q.

AU - Wainwright, Derek A.

AU - Lee-Chang, Catalina

AU - Miska, Jason

AU - Sonabend, Adam M.

AU - Heimberger, Amy B.

AU - Lukas, Rimas V.

N1 - Funding Information: A.M.S. reports authorship of patents filed by Northwestern University regarding immunotherapy for gliomas. Research support has kindly been provided by BMS, Agenus, and Carthera. Additionally, he has received philanthropic support from Agenus. A.B.H. serves on the advisory board of Caris Life Sciences, and WCG Oncology Advisory Board receives royalty and milestone payments from DNAtrix for the licensing of “Biomarkers and combination therapies using oncolytic virus and immunomodulation” (11,065,285) and is supported by research grants from Celularity, Codiak Biosciences, and AbbVie. Other support has been provided by Moleculin and Carthera, and she has received consulting fees in the last year from Novocure and Istari Oncology. She additionally has active patents for “miRNA for treating cancer and for use with adoptive immunotherapies” (9,675,633) and “Concurrent chemotherapy and immunotherapy (9,399,662) with a patent pending for “Low intensity ultrasound combination cancer therapies” (International application #PCT/US2022/019435 and US 63/158,642). RVL serves on the scientific advisory board for Merck. Additionally, he is on the speakers’ bureau for Novocure and Merck. He receives research support from BMS. T.Q.C., D.A.W., C.L.C., and J.M. have no conflicts of interest to disclose. Funding Information: This work was supported by the following NIH grants: P30CA060553, NS110703, CA120813, NS120547, and P50CA221747. Publisher Copyright: © 2022 by the authors.

PY - 2022/8

Y1 - 2022/8

N2 - Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

AB - Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

KW - glioblastoma

KW - immune system

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85137378073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137378073&partnerID=8YFLogxK

U2 - 10.3390/cancers14164023

DO - 10.3390/cancers14164023

M3 - Review article

C2 - 36011015

AN - SCOPUS:85137378073

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 16

M1 - 4023

ER -

Next Steps for Immunotherapy in Glioblastoma

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this